VEGF and HIFα are established therapeutic targets in RCC, with drugs such as sunitinib and belzutifan achieving monotherapy efficacy by exploiting this cancer’s dependence on angiogenesis [145,146]. This evidence concerns the gene VEGFA and cancer.